GB9614871D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB9614871D0
GB9614871D0 GBGB9614871.3A GB9614871A GB9614871D0 GB 9614871 D0 GB9614871 D0 GB 9614871D0 GB 9614871 A GB9614871 A GB 9614871A GB 9614871 D0 GB9614871 D0 GB 9614871D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9614871.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GBGB9614871.3A priority Critical patent/GB9614871D0/en
Publication of GB9614871D0 publication Critical patent/GB9614871D0/en
Priority to DK97933665T priority patent/DK0912730T3/da
Priority to ES97933665T priority patent/ES2321245T3/es
Priority to DE69739186T priority patent/DE69739186D1/de
Priority to EP97933665A priority patent/EP0912730B1/en
Priority to AT97933665T priority patent/ATE419345T1/de
Priority to CA002260288A priority patent/CA2260288A1/en
Priority to AU36939/97A priority patent/AU732725B2/en
Priority to IL12803497A priority patent/IL128034A0/xx
Priority to JP50560898A priority patent/JP4177457B2/ja
Priority to NZ333722A priority patent/NZ333722A/xx
Priority to PCT/EP1997/003715 priority patent/WO1998002454A2/en
Priority to ARP970103142A priority patent/AR007737A1/es
Priority to ZA976216A priority patent/ZA976216B/xx
Priority to CO97039907A priority patent/CO4750673A1/es
Priority to TW086110188A priority patent/TW538048B/zh
Priority to IL128034A priority patent/IL128034A/en
Priority to US09/612,314 priority patent/US6713606B1/en
Priority to US10/742,887 priority patent/US7655617B2/en
Priority to IL16605104A priority patent/IL166051A0/xx
Priority to US12/192,560 priority patent/US20100286367A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
GBGB9614871.3A 1996-07-15 1996-07-15 Compounds Pending GB9614871D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB9614871.3A GB9614871D0 (en) 1996-07-15 1996-07-15 Compounds
PCT/EP1997/003715 WO1998002454A2 (en) 1996-07-15 1997-07-08 Conjugates of soluble peptidic compounds with membrane-binding agents
NZ333722A NZ333722A (en) 1996-07-15 1997-07-08 Soluble fatty acid derived peptide each with binding element more than 5kD as medicaments for disorders associated with inflammation or inappropriate complement activation
ES97933665T ES2321245T3 (es) 1996-07-15 1997-07-08 Conjugados de compuestos peptidicos solubles con agentes de union a membranas.
DE69739186T DE69739186D1 (de) 1996-07-15 1997-07-08 Konjugate von löslichen peptidischen verbindungen mit membranbindenden wirkstoffen
EP97933665A EP0912730B1 (en) 1996-07-15 1997-07-08 Conjugates of soluble peptidic compounds with membrane-binding agents
AT97933665T ATE419345T1 (de) 1996-07-15 1997-07-08 Konjugate von löslichen peptidischen verbindungen mit membranbindenden wirkstoffen
CA002260288A CA2260288A1 (en) 1996-07-15 1997-07-08 Conjugates of soluble peptidic compounds with membrane-binding agents
AU36939/97A AU732725B2 (en) 1996-07-15 1997-07-08 Conjugates of soluble peptidic compounds with membrane-binding agents
IL12803497A IL128034A0 (en) 1996-07-15 1997-07-08 Conjugates of soluble peptidic compounds with membrane-binding agents
JP50560898A JP4177457B2 (ja) 1996-07-15 1997-07-08 膜結合剤と可溶性ペプヂド性化合物の結合体
DK97933665T DK0912730T3 (da) 1996-07-15 1997-07-08 Konjugater af opl selige peptidforbindelser med membranbindende stoffer
ZA976216A ZA976216B (en) 1996-07-15 1997-07-14 Conjugates of soluble peptidic compounds with membrane-binding agents
ARP970103142A AR007737A1 (es) 1996-07-15 1997-07-14 Un derivado de un peptido soluble, un procedimiento para su preparacion, una porcion polipeptidica del mismo, un polimero de adn, un vector de expresionreplicable, una celula huesped, un elemento peptidico modificado que se une a la membrana, una composicion farmaceutica que comprende dicho derivado y el uso
CO97039907A CO4750673A1 (es) 1996-07-15 1997-07-15 Derivados solubles compuestos de polipeptidos solubles y elementos que se unen a membrana
TW086110188A TW538048B (en) 1996-07-15 1997-07-18 A soluble derivative of a soluble polypeptide and its use
IL128034A IL128034A (en) 1996-07-15 1999-01-13 Conjugates of soluble peptidic compounds with membrane-binding agents
US09/612,314 US6713606B1 (en) 1996-07-15 2000-07-07 Conjugates of soluble peptidic compounds with membrane-binding agents
US10/742,887 US7655617B2 (en) 1996-07-15 2003-12-23 Conjugates of soluble peptidic compounds with membrane-binding agents
IL16605104A IL166051A0 (en) 1996-07-15 2004-12-30 Membrane localization reagent
US12/192,560 US20100286367A1 (en) 1996-07-15 2008-08-15 Conjugates of soluble peptidic compounds with membrane-binding agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9614871.3A GB9614871D0 (en) 1996-07-15 1996-07-15 Compounds

Publications (1)

Publication Number Publication Date
GB9614871D0 true GB9614871D0 (en) 1996-09-04

Family

ID=10796956

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9614871.3A Pending GB9614871D0 (en) 1996-07-15 1996-07-15 Compounds

Country Status (17)

Country Link
US (3) US6713606B1 (enExample)
EP (1) EP0912730B1 (enExample)
JP (1) JP4177457B2 (enExample)
AR (1) AR007737A1 (enExample)
AT (1) ATE419345T1 (enExample)
AU (1) AU732725B2 (enExample)
CA (1) CA2260288A1 (enExample)
CO (1) CO4750673A1 (enExample)
DE (1) DE69739186D1 (enExample)
DK (1) DK0912730T3 (enExample)
ES (1) ES2321245T3 (enExample)
GB (1) GB9614871D0 (enExample)
IL (3) IL128034A0 (enExample)
NZ (1) NZ333722A (enExample)
TW (1) TW538048B (enExample)
WO (1) WO1998002454A2 (enExample)
ZA (1) ZA976216B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
GB9704519D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Compounds
CA2312009A1 (en) 1997-11-28 1999-06-10 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
EP0953576B1 (en) 1998-04-30 2005-11-02 Curis, Inc. Active hedgehog protein conjugate, process for its production and use
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
GB0016811D0 (en) * 2000-07-07 2000-08-30 Adprotech Ltd Lipid rafts
GB0026924D0 (en) 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
GB0117193D0 (en) * 2001-07-13 2001-09-05 Adprotech Ltd Protein modification reagents
GB0123262D0 (en) * 2001-09-27 2001-11-21 Adprotech Ltd Polymeric compounds
GB0220936D0 (en) * 2002-09-05 2002-10-23 Adprotech Ltd Modified therapeutic agents
FR2854897B1 (fr) * 2003-05-12 2007-05-04 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane.
US7858108B2 (en) * 2003-10-21 2010-12-28 Richard Nagler Elutable surface coating
US8454963B2 (en) * 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
WO2005069726A2 (en) * 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
WO2005115430A1 (en) 2004-05-27 2005-12-08 Gropep Limited Treatment of inflammatory airway disease
JP2009508937A (ja) * 2005-09-22 2009-03-05 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Ｔ細胞免疫を調節するためのジアステレオマーペプチド
ATE487488T1 (de) 2006-03-09 2010-11-15 Cambridge Entpr Ltd Neuartige antibiotische zusammensetzungen
EP2083841B1 (en) 2006-10-20 2013-11-20 Celldex Therapeutics, Inc. SOLUBLE COMPLEMENT RECEPTOR TYPE I (sCR1) PROTEIN FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER DISEASES OF THE EYE
WO2008104979A2 (en) * 2007-02-28 2008-09-04 Yeda Research And Development Co. Ltd. Nuclear targeting sequences
WO2010034015A2 (en) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
US20120040886A1 (en) * 2009-02-20 2012-02-16 Zheng Xin Dong Analogues of Neuropeptide Y Having Proline Substitution At Position 34
EP2419119B1 (en) * 2009-04-16 2017-06-07 Ruprecht-Karls-Universität Heidelberg Muscle function enhancing peptide
GB0915519D0 (en) 2009-09-04 2009-10-07 King S College London Ntithrombotic compounds
WO2011050334A1 (en) * 2009-10-22 2011-04-28 Yong Zhu Compositions and methods for re-programming cells without genetic modification for treatment of obesity and related diseases
AU2011301996A1 (en) 2010-09-15 2013-03-21 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
CA2815237C (en) 2010-10-27 2018-10-09 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
JP6138815B2 (ja) * 2011-12-01 2017-05-31 エーピー バイオサイエンシーズ， インコーポレイテッド 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法
US9987235B2 (en) 2013-08-01 2018-06-05 Nicholas L. Abbott Methods and compositions for modifying mucous membranes
EP3046929B1 (en) 2013-09-17 2019-01-16 Yeda Research and Development Co., Ltd. Erk-derived peptides and uses thereof
GB201402267D0 (en) 2014-02-10 2014-03-26 Cambridge Entpr Ltd Antibacterial agents
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN110240656A (zh) * 2019-04-24 2019-09-17 中山大学附属第三医院 一种融合蛋白及其制备方法与应用
CN110551177A (zh) * 2019-08-29 2019-12-10 安徽瑞达健康产业有限公司 多肽、多肽衍生物、多肽-抗体复合物及制备、应用
GB201913804D0 (en) 2019-09-25 2019-11-06 Prostate Cancer Res Centre Fusion polypeptides
WO2024092160A2 (en) * 2022-10-26 2024-05-02 Flagship Pioneering Innovations Vii, Llc Bifunctional proteases and uses thereof
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536391A (en) 1982-11-17 1985-08-20 Otsuka Pharmaceutical Co. Process for preparing urokinase complex
EP0114787B1 (de) * 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
GB8334498D0 (en) 1983-12-24 1984-02-01 Beecham Group Plc Compounds
GB8400653D0 (en) 1984-01-11 1984-02-15 Beecham Group Plc Conjugates
ES8801374A1 (es) 1985-04-04 1988-01-01 Beecham Group Plc Un procedimiento para preparar un activante de plasminogeno.
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
JP2573007B2 (ja) * 1987-12-28 1997-01-16 株式会社成和化成 修飾された動物毛粉末
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5582968A (en) * 1990-02-16 1996-12-10 United Biomedical, Inc. Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US5326700A (en) 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
WO1993022343A1 (en) * 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
US5833989A (en) * 1992-06-24 1998-11-10 Adprotech Plc Soluble CR1 derivatives
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
JP3662021B2 (ja) * 1993-05-17 2005-06-22 アーヴァント イミュノセラピューティクス インコーポレイテッド 補体関連蛋白質および炭水化物よりなる組成物、ならびに該組成物の製法および使用方法
AU683158B2 (en) * 1994-03-03 1997-10-30 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US5776689A (en) 1996-07-19 1998-07-07 The Regents Of The University Of California Protein recruitment system
EP1119772A1 (en) 1998-10-01 2001-08-01 Alexey Vladimirovich Titievsky A novel ret-independent signaling pathway for gdnf
GB0220936D0 (en) * 2002-09-05 2002-10-23 Adprotech Ltd Modified therapeutic agents

Also Published As

Publication number Publication date
CA2260288A1 (en) 1998-01-22
IL166051A0 (en) 2006-01-15
NZ333722A (en) 2000-09-29
JP2000515370A (ja) 2000-11-21
JP4177457B2 (ja) 2008-11-05
AU3693997A (en) 1998-02-09
US20040266684A1 (en) 2004-12-30
US7655617B2 (en) 2010-02-02
ATE419345T1 (de) 2009-01-15
IL128034A0 (en) 1999-11-30
US6713606B1 (en) 2004-03-30
WO1998002454A3 (en) 1998-04-02
US20100286367A1 (en) 2010-11-11
TW538048B (en) 2003-06-21
WO1998002454A2 (en) 1998-01-22
CO4750673A1 (es) 1999-03-31
ES2321245T3 (es) 2009-06-03
EP0912730B1 (en) 2008-12-31
IL128034A (en) 2007-03-08
ZA976216B (en) 1999-04-14
DE69739186D1 (de) 2009-02-12
AU732725B2 (en) 2001-04-26
DK0912730T3 (da) 2009-04-27
AR007737A1 (es) 1999-11-10
EP0912730A2 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
GB9614871D0 (en) Compounds
GB9607120D0 (en) Compounds
GB9616643D0 (en) Compounds
GB9602326D0 (en) Compounds
GB9612153D0 (en) Compounds
GB9606933D0 (en) Compounds
GB9610902D0 (en) Compounds
GB9615792D0 (en) Compounds
GB9607122D0 (en) Compounds
GB9607126D0 (en) Compounds
GB9607154D0 (en) Compounds
GB9607155D0 (en) Compounds
GB9607215D0 (en) Compounds
GB9607218D0 (en) Compounds
GB9607256D0 (en) Compounds
GB9607438D0 (en) Compounds
GB9607444D0 (en) Compounds
GB9607723D0 (en) Compounds
GB9607724D0 (en) Compounds
GB9607739D0 (en) Compounds
GB9607847D0 (en) Compounds
GB9608367D0 (en) Compounds
GB9609403D0 (en) Compounds
GB9609888D0 (en) Compounds
GB9615791D0 (en) Compounds